Evommune, Inc. filed a current report on November 4, 2026, disclosing an exclusive license agreement with Hinova Pharmaceuticals Inc. for VAV1 degrader EVO570 and a concurrent $30.0 million private placement of common stock.

Key Highlights

  • Exclusive license secured: Evommune obtained worldwide rights (excluding Greater China) to develop, manufacture, and commercialize Hinova's VAV1 degraders, including molecular glue degrader EVO570 (formerly HC118).
  • Upfront consideration: The company agreed to pay Hinova a one-time, non-refundable $20.0 million cash payment and issue pre-funded warrants to purchase up to 1,262,413 shares of common stock, representing $10.0 million of common stock.
  • Milestone potential: Hinova is eligible to receive up to $150.0 million in development and regulatory milestones and up to $920.0 million in commercial milestones, plus tiered royalties ranging from mid single-digits to low double-digits on net sales.
  • Warrant terms: The pre-funded warrants carry an exercise price of $0.001 per share and are exercisable immediately, expiring November 4, 2036, subject to a 4.99% beneficial ownership limitation.
  • Private placement: Evommune agreed to sell 4,966,889 shares of common stock at $6.04 per share, with estimated gross proceeds of approximately $30.0 million before transaction-related expenses.
  • Placement agents: Morgan Stanley & Co. LLC and Leerink Partners LLC acted as placement agents; Oppenheimer & Co. Inc. acted as capital markets advisor.
  • Registration obligation: The company is required to file a Form S-3 registration statement to register the placed shares for resale within 60 days of closing, with effectiveness targeted no later than 90 days after that filing.

Evommune Enters VAV1 License and $30 Million Private Placement on November 4, 2026

According to the filing, Evommune, Inc. (NYSE:EVMN) entered into an Exclusive License Agreement with Hinova Pharmaceuticals Inc., a company incorporated in the People's Republic of China, on November 4, 2026. Under the agreement, Hinova granted Evommune exclusive and sublicensable rights to develop, manufacture, commercialize, and otherwise exploit Hinova's VAV1 degraders, including EVO570, across all human and animal indications worldwide except mainland China, Hong Kong, Macau, and Taiwan, where Hinova retained all rights.

The company disclosed that upfront consideration consists of a $20.0 million non-refundable cash payment and pre-funded warrants to a wholly owned subsidiary of Hinova covering up to 1,262,413 shares of Evommune common stock at an exercise price of $0.001 per share. The warrant share count was calculated based on the average closing price of the company's common stock over the 45 consecutive trading days immediately preceding the agreement date, equating the warrants to $10.0 million of common stock. The filing states that royalty payments will apply on a product-by-product and country-by-country basis, running through the latest of patent expiration, regulatory exclusivity expiration, or the 10-year anniversary of the first commercial sale in a given country.

Separately, the company disclosed that it entered into a Securities Purchase Agreement on the same date with certain investors for a private placement of 4,966,889 shares of common stock at $6.04 per share, with an expected closing on or about November 6, 2026. The company stated it intends to use net proceeds to advance its clinical development programs and for general corporate purposes. Pursuant to a Registration Rights Agreement executed concurrently, Evommune is obligated to file a Form S-3 registration statement within 60 days of the private placement closing and use reasonable best efforts to have it declared effective no later than 90 days after that initial filing.

What Was Disclosed

Evommune disclosed an exclusive license for VAV1 degrader EVO570 from Hinova, with $20.0 million upfront cash, warrants for 1,262,413 shares, and up to $1.07 billion in potential milestones, alongside a concurrent approximately $30.0 million private placement of common stock.